Funding, M&A, exec moves and hiring — matched to your market, with the people to call.See plans →
Cagent Vascular Closes An Oversubscribed $41 M Series D Financing To Advance Its Serranator® Sonic Ivl System For Clinical Launch And Coronary Program Development. announced it raised $41 Million in an initial filing from an offering of $41 Million
PRIVATEMay 19, 2026•3 months ago
Amount Raised
$41 Million
Round Type
Series D
WayneHealthcareHealth Care
Investors
Usvp
Description
Cagent Vascular, Inc. has announced the successful first human use of its Serranator® SONIC Intravascular Lithotripsy (IVL) System and has closed a $41 million Series D financing round. The funds will support the clinical advancement and commercialization of the company's dual-modality IVL platform. This funding marks a significant milestone in Cagent's development of its innovative IVL technologies
Company Information
Company
Cagent Vascular
Location
150 STRAFFORD AVENUE
Wayne, Pennsylvania, United States
About
Cagent Vascular has developed and commercialized its novel angioplasty balloon with Serration Technology to treat blocked arteries in the leg or Peripheral Artery Disease (PAD) and Chronic Limb Threatening Ischemia (CLTI). The Serranator PTA Serration Balloon Catheter is the first and only angioplasty balloon with serration technology.
Related People
Suggested for you
1 contact
Verified contactsRobert G., Director
Predictive Intelligence
Strategic
ML-powered predictions for Cagent Vascular's next move
WayneHealthcareHealth Care